All News
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD
Links:
Dr. John Cush RheumNow ( View Tweet)
The Safety of Rituximab and JAK Inhibitors with post-COVID Vaccination
At the onset of the pandemic, data from the Global Rheumatology Alliance reported increased risk of poor severe COVID outcomes including deaths in patients who were treated with rituximab and baricitinib. With the vaccination program undertaken globally, has this risk been attenuated?
Read Article
Spondyloarthritis and COVID-19
With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022
https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL
Links:
Dr. John Cush RheumNow ( View Tweet)
Biosimilars and COVID vaccines have made nocebo more pertinent than ever.
How do we combat it?
First line is good communication, and the foot soldiers are the right phrases.
Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G
David Liew drdavidliew ( View Tweet)
Rituximab/belimumab patients & COVID vaccination response:
may have had average antibody response
but there’s still the cellular response to consider too! Not as bad.
Still caution++, but when ritux really needed we’ll find a way despite COVID
from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG
David Liew drdavidliew ( View Tweet)
Sreekanth et al. 2 studies re holding MTX after both doses vs only 2nd dose of AZ COVID vaccine. Either holding strategy increased ab titres. Only holding 2nd non-inferior to holding both with decreased flares @RheumNow #EULAR2022 LB0003 https://t.co/aCOEdXp4ol https://t.co/XAZyBojryK
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 LB0006
SAPHYR: P3 trial, 52 wk: Sarilumab in relapsing PMR
Study terminated early due to COVID recruitment
⭐️Sustained remission: 28 vs 10%, primary endpt
⭐️HR of flare 0.56 on Sarilumab
⭐️Less steroid usage, glucocorticoid tox score
@Rheumnow https://t.co/5PP1YP7YtU
Eric Dein ericdeinmd ( View Tweet)
#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2022 LB003: W/d MTX w COVID vax
MIVAC 1: hold MTX both vax vs continuing
MIVAC 2: hold after 2nd dose only vs continuing
⭐️MTX hold: improved Ab titers, no diff in MIVAC1/2
⭐️Higher reported flare for holding with both doses (36%) vs just 2nd dose (12%)
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#COVID19 #pandemic has affected #rheumatology training
Negative impact on
▶️Learning
▶️Research
▶️Mental health
▶️Physical health
👉🏽https://t.co/Irtkg8TjZt
By @kristenyoung @SuAnnYeoh1 @EBRheum @SattuiSEMD @RichardPAConway @SituationRheum @KilianMD @rheum_covid et al @RheumJnl https://t.co/wysWzE92Fm
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Yusof et al @Yuz6Yusof COVID-19 in RTX treated patients. Significant efficacy of vaccination in both overall and severe COVID rates. Vaccination decreased risk HR 0.13 (0.03-0.51). Number comorbidities and low IgG increase risk @RheumNow #EULAR2022 OP0250 https://t.co/yD1tvs1UYt https://t.co/23XTtPb8fD
Links:
Richard Conway RichardPAConway ( View Tweet)
Roberto Giacomeilli from Italy explaining the mechanisms on how COVID-19 may cause rheumatic disease #EULAR2022 @RheumNow https://t.co/a2kTT7vcRx
Dr. Antoni Chan synovialjoints ( View Tweet)
COVID-19 mostly mild for majority of SpA patients.
Steroid use associated with more severe COVID-19 outcomes (OR 3.15).
TNFi found to be protective! (OR 0.26)
@RheumNow #EULAR2022 ABST#OP0254
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 POS0196 found 9% of post-COVID19 patients developed MSK symptoms. @RheumNow https://t.co/YFT83TjXFL
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Yeoh @SuAnnYeoh1 @rheum_covid Factors assoc severe COVID outcomes in IIM. Age, male, high disease activity, 2+ comorbidities, pred>7.5mg, RTX, assoc hospitalisation or death @RheumNow #EULAR2022 OP0252 https://t.co/PvCeSX8UvF https://t.co/RaISpeUNsH
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 POS0199 showed marked decrease in SARS-CoV2 IgG ab 6 months after initial two dose vaccines. @RheumNow https://t.co/lZdWQUqFvf
Dr. Rachel Tate uptoTate ( View Tweet)
#OP0252 #EULAR2022 Dr Yeoh presented data from Global Rheum Alliance of >300 pts with myositis. 13% died. Usual suspects re: Factors assoc with poor #COVID outcome: age, active disease,on steroid,male and RTX exposure. Be interesting to see longer followup post-booster @RheumNow https://t.co/F7qaee5ADK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)